BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $426,554 | +363.6% | 14,608 | +43.2% | 0.00% | – |
| Q2 2022 | $92,000 | -13.2% | 10,201 | -0.7% | 0.00% | – |
| Q1 2022 | $106,000 | -94.0% | 10,273 | -91.5% | 0.00% | -100.0% |
| Q4 2021 | $1,759,000 | -71.8% | 120,460 | -4.9% | 0.00% | -66.7% |
| Q3 2021 | $6,242,000 | +13.8% | 126,665 | +39.1% | 0.00% | 0.0% |
| Q2 2021 | $5,484,000 | +13.2% | 91,039 | +9.2% | 0.00% | 0.0% |
| Q1 2021 | $4,844,000 | +507.0% | 83,346 | +616.5% | 0.00% | +200.0% |
| Q4 2020 | $798,000 | +439.2% | 11,632 | +208.6% | 0.00% | – |
| Q3 2020 | $148,000 | -24.5% | 3,769 | -38.0% | 0.00% | – |
| Q2 2020 | $196,000 | +684.0% | 6,082 | +499.8% | 0.00% | – |
| Q1 2020 | $25,000 | -81.5% | 1,014 | -73.6% | 0.00% | – |
| Q4 2019 | $135,000 | +45.2% | 3,846 | -11.2% | 0.00% | – |
| Q3 2019 | $93,000 | -65.6% | 4,332 | -56.7% | 0.00% | – |
| Q2 2019 | $270,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |